XFOR · X4 Pharmaceuticals, Inc · Investor Relations

The latest filing states the doubt was alleviated.

“The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. Although the Company has an approved drug product, licensing and sales of the Company's drug product over the next 12 months will not be sufficient to fund the Company's operating expenses. Since inception, the Company has incurred significant operating losses and negative cash flows from operations, and the Company expects to continue to generate operating losses and negative cash flows from operations for the foreseeable future. For the six months ended June 30, 2026, the Company's net loss was $36.4 million and net cash used in operating activities was $40.4 million. As of June 30, 2026, the Company had $208.0 million of cash, cash equivalents and short-term marketable securities, and an accumulated deficit of $631.0 million. Based on its current operating plan, the Company believes (a) that its current cash, cash equivalents and short-term marketable securities will be sufficient to fund its operations and debt obligations for at least the next 12 months and (b) it will continue to comply with all covenants under the Hercules Loan Agreement, as defined and further described in Note 9, through at least the 12-month period from the issuance date of these condensed consolidated financial statements.”